Nano Dimension — Update 21 November 2016

Nano Dimension — Update 21 November 2016

Nano Dimension

Analyst avatar placeholder

Written by

Nano Dimension

Major commercialisation milestones reached

Q316 results

Tech hardware & equipment

17 November 2016

Price*

NIS4.99

Market cap

NIS248m

*Priced at 15 November 2026

NIS3.80:US$

Net cash (US$m) at end September 2016
Including receipt of $12.0m funding (gross) from open offer, but excluding $1.8m (gross) from over-allocation of options.

14.2

Shares in issue

49.6m

ADRs in issue

9.9m

Free float

62%

Code

NNDM

Primary exchange

TASE

Secondary exchange

NASDAQ

Share price performance

%

1m

3m

12m

Abs

(8.8)

(1.8)

(27.5)

Rel (local)

(6.0)

2.2

(19.2)

52-week high/low

NIS7.2

NIS4.5

Business description

Nano Dimension focuses on the development of advanced 3D printed electronics systems and advanced additive manufacturing. The company’s initial products include a 3D printer for rapid prototyping of multi-layer PCBs and associated nanotechnology conductive and dielectric inks.

Next event

FY16 results

March 2017

Analysts

Anne Margaret Crow

+44 (0)20 3077 5700

Dan Ridsdale

+44 (0)20 3077 5729

Q3 was an exciting quarter for Nano Dimension as it delivered its first DragonFly systems to potential customers for evaluation and raised US$13.8m (gross) to provide finance as it moves into the commercial phase of development. The company appears on track to complete the beta testing phase mid-2017 and to deliver 50 printers during FY17. However, we have revised our estimates down to model the impact of moving to a leasing model during the beta test phase while leaving our indicative valuation broadly unchanged.

Year
end

Revenue (US$m)

EBITDA**
(US$m)

PBT*
(US$m)

EPADS
(US$)

DPADS
(US$)

P/E
(x)

12/15***

0.0

(2.4)

(2.1)

(0.39)

0.00

N/A

12/16e

0.0

(4.9)

(5.0)

(0.60)

0.00

N/A

12/17e

5.2

(8.6)

(8.8)

(0.89)

0.00

N/A

12/18e

35.7

11.3

11.0

0.93

0.00

1.4

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. **EBITDA is stated after deducting amortisation of capitalised R&D. ***Translated from NIS.

Major milestones to commercialisation reached

Nano Dimension delivered the first two DragonFly 2020 printers for evaluation during Q3. The first went to an Israeli defence company, the second to a distribution partner in California. Management notes that feedback so far has been positive. All of this will potentially generate leasing revenues, although maximising this is less important than getting technical feedback and establishing long-term relationships with quality customers. Management expects to deliver a total of 50 printers during FY17, including around 35 in the commercial roll-out during H217 and to scale this up further during FY18.

Placing to fund commercialisation phase

Operating losses reduced by 1% sequentially during Q316 to US$1.7m (28% increase y-o-y) as the number of people engaged in R&D rose to 67 but professional services and other general expenses reduced. Nano Dimension raised US$12.0m (gross) during the quarter through a placing and a further $1.8m (gross) through an over-allotment option, both at US$6.50/ADS. The funds will be used to support the ramp-up in volume, including a c US$1.5m investment in expanding the ink production capability. Management expects this to be in place during Q217, ahead of the commencement of volume sales in H217. According to management, cash burn is currently around $1m/month.

Valuation: Significant upside on volume roll-out

Delivery to our estimates and key milestones over the next year would justify significant share price appreciation, with our base case valuation returning a fair value of NIS9.87/ordinary share, US$12.97/ADS (NIS9.93/ordinary share, US$12.86/ADS before the fund-raising), excluding any additional potential contribution from third-party ink sales or early-stage development programmes. The current share price factors in the risks of setbacks to the commercialisation plan, which is common in pre-revenue technology companies.

PCB sector roll-out programme on track

In August Nano Dimension delivered the first DragonFly 2020 system for creating multilayer printed circuit boards to a leading defence company in Israeli for evaluation. Less than a month later, it delivered the first DragonFly to the US. This system is being used by FATHOM, Nano Dimension’s partner, to support demonstrations and product evaluations in the US, especially to potential customers in Silicon Valley and the greater West Coast area. Initial feedback from both beta sites appears to be positive, with the main comments being requests for additional functions in the software provided with the printers; these are to be expected. The first version of the Switch software was released in July 2016. It is not possible to anticipate all the functionality requirements until customers start to use the software themselves. This highlights why Nano Dimension is keen to have an extended beta test phase with customers that will provide detailed feedback. This will enable it to refine both the software and the printer so that they are suitable for volume deployment.

Following the initial feedback from the two beta sites, management has confirmed that the roll-out programme is on track, with a further four printers scheduled for delivery to beta site customers by the end of FY16, 50 for FY17, of which around 35 will be for the commercial roll-out during H217. These volumes will be scaled up further during FY18. As the first printers for beta site delivery have become available, management has intensified discussions with potential beta site customers. As a result, it has decided it is better to adopt a leasing model during this phase than a straight sales model. This means that revenues will not be recognised up-front, affecting the top-line P&L, but enables Nano Dimension to select beta site partners on the basis of their ability to provide useful feedback and ultimately, to become long-term customers. The cash raised from the recent open offer and exercise of over-allotment option enables management to pursue this route.

Nano Dimension is using some of the funds raised to expand the ink production facility so that it can provide the quantity needed once it enters the commercial phase and the volumes of printers being sold ramps up. It has leased another floor in its existing facility in Ness Ziona near Tel Aviv to accommodate ink production. Management expects the new facility, which will cost an estimated $1.5m, to be opened Q217. We model most of the cost of this as falling in FY17.

Progress in other sectors

Although Nano Dimension is highly focused on completing the beta test for the PCB (printed circuit board) printer and software, it has made significant progress in developing 3D print systems for other sectors. During Q3 it conducted a successful test for 3D printing of conductive traces on to fabric to create smart textiles and filed a patent for a higher conductivity ink, potentially accelerating print speeds and reducing the quantities of ink required. Following the successful demonstration of 3D printing human tissue and organs during Q216, management has confirmed that it will form a separate subsidiary to commercialise this opportunity.

Financials

Changes to estimates

We update our estimates from those shown in the October edition of Edison Insight to reflect that, although the roll-out schedule for DragonFly printers is on track, management now expects to adopt a leasing model during the beta testing phase. We also make changes to recognise share-based payments (US$1.8m non-cash charge recognised in the first nine months of FY16) and a probable change in the way in which R&D costs are treated. Our previous estimates assumed that a material proportion of R&D costs would be capitalised in FY16, FY17 and FY18. Based on the company’s guidance, our revised treatment assumes that 71% of R&D costs will be capitalised in FY16, while all R&D costs will be expensed in both FY17 and FY18.

Exhibit 1: Changes to estimates

Revenues (US$m)

EBITDA (US$m)

Adjusted PBT (US$m)

Adjusted EPADS (US$)

Old*

New

% change

Old*

New

% change

Old*

New

% change

Old*

New

% change

2015

0.0

0.0

N/A

(5.7)

(2.4)

-58

(5.4)

(2.1)

-61

(1.00)

(0.39)

-61

2016e

0.2

0.0

-100

(5.4)

(4.9)

-9

(5.6)

(5.0)

-11

(0.67)

(0.60)

-10

2017e

6.5

5.2

-20

(3.8)

(8.6)

+126

(4.0)

(8.8)

+120

(0.41)

(0.89)

+117

2018e

35.7

35.7

N/A

14.4

11.3

-22

14.1

11.0

-22

1.20

0.93

-23

Source: Edison Investment Research. Note: *Estimates as shown in October edition of Edison Insight, which includes impact of open offer and over-allocation of options.

Increased investment in R&D

Operating losses reduced by 1% sequentially during Q316 to US$1.7m (28% increase y-o-y). The number of people engaged in R&D rose from 57 at the end of June to 67 at the end of September. This was offset by a reduction in the cost of professional services and other general expenses.

Placing to fund commercialisation phase

Nano Dimension raised US$12.0m (gross) during Q3 through a placing and a further $1.8m (gross) through an over-allotment option during early Q416, both at US$6.50/ADS. The funds will be used to support the ramp-up in volume, including a c US$1.5m investment in expanding the ink production capability. Management expects this to be in place during Q217, ahead of the start of volume sales in H217. According to management, cash burn is currently around $1m/month. Our model shows Nano Dimension has sufficient cash to support it through the commercialisation phase of the 3D print system for PCBs provided it achieves the roll-out rate and pricing assumed in our estimates (see our September note for details). We note that management intends to establish a separate entity for commercialising 3D print of biological tissues. This will be financed separately from the PCB programme.

Valuation

We update our indicative valuation to reflect the shift to a leasing model during the beta phase. This analysis excludes any additional potential contribution from third-party ink sales or early stage development programmes. Further progress against major milestones should act as a catalyst to push the share price beyond the current level towards our indicative value of NIS9.87/ordinary share, US$12.97/ADS (NIS9.93/ordinary share, US$12.86/ADS prior to the fund-raising).

Exhibit 2: Edison DCF analysis

US$m/ADS

Base case

NIS/ordinary share

Base case

Discount rate

Discount rate

11.0%

13.0%

15.0%

11.0%

13.0%

15.0%

Terminal Growth

0.0%

14.62

11.80

9.78

0.0%

11.13

8.98

7.44

1.0%

15.50

12.34

10.13

1.0%

11.80

9.39

7.71

2.0%

16.58

12.97

10.53

2.0%

12.62

9.87

8.01

3.0%

17.92

13.74

10.99

3.0%

13.64

10.45

8.37

4.0%

19.65

14.67

11.55

4.0%

14.95

11.16

8.79

Source: Edison Investment Research

Exhibit 3: Financial summary

US$000

2015*

2016e

2017e

2018e

Year-end 31 December

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

 

0

36

5,160

35,680

Cost of Sales (including amortisation of capitalised IP)

0

(9)

(2,728)

(12,764)

Gross Profit

0

27

2,432

22,916

EBITDA

 

 

(2,437)

(4,873)

(8,636)

11,329

Operating Profit (before amort. and except.)

(2,473)

(4,986)

(8,797)

11,016

Intangible Amortisation

0

0

0

0

Exceptionals

0

0

0

0

Other

(3,262)

(2,000)

(2,000)

(2,000)

Operating Profit

(5,735)

(6,986)

(10,797)

9,016

Net Interest

355

0

0

0

Profit Before Tax (norm)

 

 

(2,118)

(4,986)

(8,797)

11,016**

Profit Before Tax (FRS 3)

 

 

(5,380)

(6,986)

(10,797)

9,016

Tax

0

0

0

0

Profit After Tax (norm)

(2,118)

(4,986)

(8,797)

9,254

Profit After Tax (FRS 3)

(5,380)

(6,986)

(10,797)

9,016

Average Number of Shares Outstanding (m)

5.4

8.3

9.9

9.9

EPADS - normalised ($)

 

 

(0.39)

(0.60)

(0.89)

0.93**

EPADS - normalised fully diluted ($)

 

 

(0.39)

(0.60)

(0.89)

0.69**

EPADS - (IFRS) ($)

 

 

(1.00)

(0.84)

(1.09)

0.91

DPADS ($)

0.0

0.0

0.0

0.0

Gross Margin (%)

N/A

74.0

47.1

64.2

EBITDA Margin (%)

N/A

N/A

N/A

31.8

Operating Margin (before GW and except.) (%)

N/A

N/A

N/A

30.9

BALANCE SHEET

Fixed Assets

 

 

4,151

10,372

10,653

9,681

Intangible Assets

2,910

8,653

7,417

6,357

Tangible Assets

1,131

1,609

3,126

3,214

Restricted deposits

110

110

110

110

Current Assets

 

 

9,057

12,918

4,374

21,942

Stocks

0

100

350

1,350

Debtors

264

314

1,064

6,644

Cash

8,665

12,376

2,832

13,820

Restricted deposits

128

128

128

128

Current Liabilities

 

 

(907)

(1,707)

(2,457)

(8,037)

Creditors

(907)

(1,707)

(2,457)

(8,037)

Short-term borrowings

0

0

0

0

Long-Term Liabilities

 

 

(254)

(330)

(363)

(182)

Long-term borrowings

0

0

0

0

Liability in respect of government grants

(254)

(330)

(363)

(182)

Net Assets

 

 

12,047

21,252

12,207

23,404

CASH FLOW

Operating Cash Flow

 

 

(3,330)

(3,923)

(7,650)

11,388

Net Interest

0

0

0

0

Tax

0

0

0

0

Investment in intangible & tangible assets

(2,344)

(6,343)

(1,894)

(400)

Acquisitions/disposals

0

0

0

0

Financing

14,362

13,977

0

0

Dividends

0

0

0

0

Net Cash Flow

8,688

3,711

(9,544)

10,988

Opening net debt/(cash)

 

 

(207)

(8,665)

(12,376)

(2,832)

HP finance leases initiated

0

0

0

0

Other

(230)

0

0

0

Closing net debt/(cash)

 

 

(8,665)

(12,376)

(2,832)

(13,820)

Source: Edison Investment Research. Note: *Translated from NIS. **Normalised for tax.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

EDISON ISRAEL DISCLAIMER

Disclosure regarding the scheme to enhance the awareness of investors to public companies in the technology and biomed sectors that are listed on the Tel Aviv Stock Exchange and participate in the scheme (hereinafter respectively “the Scheme”, “TASE”, “Participant” and/or “Participants”). Edison Investment Research (Israel) Ltd, the Israeli subsidiary of Edison Investment Research Ltd (hereinafter respectively “Edison Israel” and “Edison”), has entered into an agreement with the TASE for the purpose of providing research analysis (hereinafter “the Agreement”), regarding the Participants and according to the Scheme (hereinafter “the Analysis” or “Analyses”). The Analysis will be distributed and published on the TASE website (Maya), Israel Security Authority (hereinafter “the ISA”) website (Magna), and through various other distribution channels. The Analysis for each participant will be published at least four times a year, after publication of quarterly or annual financial reports, and shall be updated as necessary after publication of an immediate report with respect to the occurrence of a material event regarding a Participant. As set forth in the Agreement, Edison Israel is entitled to fees for providing its investment research services. The fees shall be paid by the Participants directly to the TASE, and TASE shall pay the fees directly to Edison. Subject to the terms and principals of the Agreement, the Annual fees that Edison Israel shall be entitled to for each Participant shall be in the range of $35,000-50,000. As set forth in the Agreement and subject to its terms, the Analyses shall include a description of the Participant and its business activities, which shall inter alia relate to matters such as: shareholders; management; products; relevant intellectual property; the business environment in which the Participant operates; the Participant's standing in such an environment including current and forecasted trends; a description of past and current financial positions of the Participant; and a forecast regarding future developments in and of such a position and any other matter which in the professional view of the Edison (as defined below) should be addressed in a research report (of the nature published) and which may affect the decision of a reasonable investor contemplating an investment in the Participant's securities. To the extent it is relevant, the Analysis shall include a schedule of scientific analysis of an expert in the field of life sciences. An "equity research abstract" shall accompany each Equity Research Report, describing the main points addressed. The full scope reports and reports where the investment case has materially changed will include a thorough analysis and discussion. Short update notes, where the investment case has not materially changed, will include a summary valuation discussion. The Agreement with TASE regarding the participation of Edison in the scheme for the research analysis of public companies does not and shall not constitute an approval or consent on the part of TASE or the ISA or any other exchange on which securities of the Company are listed, or any other securities’ regulatory authority which regulates the issuance of securities by the Company to the content of the Report or to the recommendation contained therein. A summary of this report is also published in the Hebrew language. In the event of any contradiction, inconsistency, discrepancy, ambiguity or variance between the English Report and the Hebrew summary of said Report, the English version shall prevail; and a note to this effect shall appear in any Hebrew summary of a Report. Edison is regulated by the Financial Conduct Authority. According to Article 12.3.2, Chapter 12 of the Conduct of Business Sourcebook, Edison, which produces or disseminates non-independent research, must ensure that it: 1) is clearly identified as a marketing communication; and 2) contains a clear and prominent statement that (or, in the case of an oral recommendation, to the effect that) it: a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and b) is not subject to any prohibition on dealing ahead of the dissemination of investment research. The financial promotion rules apply to non-independent research as though it were a marketing communication.

EDISON INVESTMENT RESEARCH DISCLAIMER

Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Tel Aviv +44 (0)20 3734 1007
Medinat Hayehudim 60,

Herzilya Pituach, 46766

Israel

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Tel Aviv +44 (0)20 3734 1007
Medinat Hayehudim 60,

Herzilya Pituach, 46766

Israel

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

EDISON ISRAEL DISCLAIMER

Disclosure regarding the scheme to enhance the awareness of investors to public companies in the technology and biomed sectors that are listed on the Tel Aviv Stock Exchange and participate in the scheme (hereinafter respectively “the Scheme”, “TASE”, “Participant” and/or “Participants”). Edison Investment Research (Israel) Ltd, the Israeli subsidiary of Edison Investment Research Ltd (hereinafter respectively “Edison Israel” and “Edison”), has entered into an agreement with the TASE for the purpose of providing research analysis (hereinafter “the Agreement”), regarding the Participants and according to the Scheme (hereinafter “the Analysis” or “Analyses”). The Analysis will be distributed and published on the TASE website (Maya), Israel Security Authority (hereinafter “the ISA”) website (Magna), and through various other distribution channels. The Analysis for each participant will be published at least four times a year, after publication of quarterly or annual financial reports, and shall be updated as necessary after publication of an immediate report with respect to the occurrence of a material event regarding a Participant. As set forth in the Agreement, Edison Israel is entitled to fees for providing its investment research services. The fees shall be paid by the Participants directly to the TASE, and TASE shall pay the fees directly to Edison. Subject to the terms and principals of the Agreement, the Annual fees that Edison Israel shall be entitled to for each Participant shall be in the range of $35,000-50,000. As set forth in the Agreement and subject to its terms, the Analyses shall include a description of the Participant and its business activities, which shall inter alia relate to matters such as: shareholders; management; products; relevant intellectual property; the business environment in which the Participant operates; the Participant's standing in such an environment including current and forecasted trends; a description of past and current financial positions of the Participant; and a forecast regarding future developments in and of such a position and any other matter which in the professional view of the Edison (as defined below) should be addressed in a research report (of the nature published) and which may affect the decision of a reasonable investor contemplating an investment in the Participant's securities. To the extent it is relevant, the Analysis shall include a schedule of scientific analysis of an expert in the field of life sciences. An "equity research abstract" shall accompany each Equity Research Report, describing the main points addressed. The full scope reports and reports where the investment case has materially changed will include a thorough analysis and discussion. Short update notes, where the investment case has not materially changed, will include a summary valuation discussion. The Agreement with TASE regarding the participation of Edison in the scheme for the research analysis of public companies does not and shall not constitute an approval or consent on the part of TASE or the ISA or any other exchange on which securities of the Company are listed, or any other securities’ regulatory authority which regulates the issuance of securities by the Company to the content of the Report or to the recommendation contained therein. A summary of this report is also published in the Hebrew language. In the event of any contradiction, inconsistency, discrepancy, ambiguity or variance between the English Report and the Hebrew summary of said Report, the English version shall prevail; and a note to this effect shall appear in any Hebrew summary of a Report. Edison is regulated by the Financial Conduct Authority. According to Article 12.3.2, Chapter 12 of the Conduct of Business Sourcebook, Edison, which produces or disseminates non-independent research, must ensure that it: 1) is clearly identified as a marketing communication; and 2) contains a clear and prominent statement that (or, in the case of an oral recommendation, to the effect that) it: a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and b) is not subject to any prohibition on dealing ahead of the dissemination of investment research. The financial promotion rules apply to non-independent research as though it were a marketing communication.

EDISON INVESTMENT RESEARCH DISCLAIMER

Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Tel Aviv +44 (0)20 3734 1007
Medinat Hayehudim 60,

Herzilya Pituach, 46766

Israel

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Tel Aviv +44 (0)20 3734 1007
Medinat Hayehudim 60,

Herzilya Pituach, 46766

Israel

Meggitt — Update 18 November 2016

Meggitt

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free